LATE-ONSET RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB AND LEFLUNOMIDE- A CASE REPORT

Rheumatoid arthritis (RA) can affect the elderly, posing distinct management and therapeutic issues. Polypharmacy is a significant concern, with a 36.4% prevalence among individuals aged 75 to 84 years. Older people are more susceptible to adverse effects due to various comorbidities and pharmacokinetic changes in metabolism and excretion. We provide a case of successfully treating late-onset RA (LORA) with baricitinib, emphasizing the importance of tailoring treatment to unique clinical conditions. We also discuss senile RA, biologics, and targeted therapies.